Novo Nordisk lost a bidding war for Metsera to Pfizer but responded by cutting Wegovy prices in India to compete in the growing obesity treatment market.

Law firm Johnson Fistel launched an investigation into potential fiduciary duty breaches by Metsera's board regarding its proposed sale to Pfizer at $47.50 per share, which is significantly below Wall Street analyst projections.

Pfizer faces challenges with upcoming patent expirations for three blockbuster drugs in 2027-2028 and a complicated acquisition attempt of Metsera, creating uncertainty about its near-term financial outlook.

A week of significant M&A activity featuring a founder's potential buyback, a heated pharmaceutical bidding war, media industry consolidation, and strategic partnerships in entertainment and aviation.

Delaware Chancery Court denied Pfizer's request to prevent Metsera from terminating their merger agreement in favor of Novo Nordisk's competing proposal. Pfizer plans to raise its bid and challenges the legality of Novo Nordisk's transaction structure.